We Can Help The costs of mesothelioma can be overwhelming. They can include income loss, expensive treatments that may not be covered by health insurance, plus pain and suffering for you and for your family. Because the disease is preventable – and because it is usually caused by someone else’s negligence – legal options may be available to help regain these costs.
Asbestos lawyers focus their practice on knowledgeably and effectively bringing to justice companies that exposed employees and the public to asbestos products.
A mesothelioma attorney can help you consider your options and file a claim against the company responsible for your asbestos-related illness. More than one company may be responsible. A mesothelioma attorney identifies all companies at fault.
Mesothelioma lawsuits have helped thousands of people receive financial assistance. A lawsuit can result in much-needed money to help reduce financial hardships during an illness and can also provide a more stable future for your loved ones. A lawyer specializing in asbestos litigation can help you seek compensation for expenses related to illness caused by asbestos exposure.
|
|
Mesothelioma researchers, advocates and physicians unite across the nation every day to change the future of mesothelioma treatment. Because of their selfless efforts, mesothelioma survivors are living longer, fuller lives with their loved ones at their side. As an advocacy organization, we continually share the latest news about medical breakthroughs and other advancements impacting the…
The post Top 10 Mesothelioma News Stories of 2016 appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.
[…]
The Mesothelioma Treatment Center at the Baylor College of Medicine Lung Institute has opened a groundbreaking clinical trial combining cytoreductive surgery with a hyperthermic, intraoperative chemotherapy lavage. Dr. David Sugarbaker, chief of thoracic surgery at Baylor and one of the world’s foremost authorities on pleural mesothelioma, believes the study could lead to a major advancement…
The post Sugarbaker Touts New Clinical Study for Mesothelioma Patients appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.
[…]
Researchers have reported more promising results from an international, multicenter phase II clinical trial of the drug nintedanib, moving it another step closer to standard-of-care treatment for pleural mesothelioma. Nintedanib is a small-molecule enzyme inhibitor being studied as a way to increase the effectiveness of chemotherapy on mesothelioma and certain types of lung cancer. Researchers…
The post Mesothelioma Trial for Nintedanib Shows Positive Results appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.
[…]
A U.S.-based study confirms what oncology experts have suggested for years — chemotherapy treatment prolongs life expectancy for malignant mesothelioma patients. Wayne State University School of Medicine researchers linked data from the National Cancer Institute’s Surveillance, Epidemiology and End Results (SEER) database with Medicare claims data. The study took into account patient characteristics such as…
The post Study Shows Impact of Chemotherapy on Mesothelioma appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.
[…]
A new analysis on how asbestos-related tumors grow may lead to more effective research and treatments of malignant mesothelioma. Researchers at Australia’s Flinders University found malignant mesothelioma tumors demonstrate vasculogenic (vascular) mimicry — the process in which tumors make their own blood vessels. Tumors promote their own growth by growing blood vessels that reach into…
The post Study Uncovers Strange Growth of Mesothelioma Tumors appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.
[…]
A new analysis on how asbestos-related tumors grow may lead to more effective research and treatments of malignant mesothelioma. Researchers at Australia’s Flinders University found malignant mesothelioma tumors demonstrate vasculogenic (vascular) mimicry — the process in which tumors make their own blood vessels. Tumors promote their own growth by growing blood vessels that reach into…
The post Study Uncovers Strange Growth of Mesothelioma Tumors appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.
[…]
A new experimental treatment combining a chemical found in red wine and a popular chemotherapy drug showed a powerful synergistic effect in targeting pleural mesothelioma cells. Researchers at Soon Chun Hyang University Hospital Cheonan in South Korea combined the platinum-based chemotherapy drug cisplatin with resveratrol, a natural antioxidant found in wine and red grapes. The…
The post Red Wine Chemical Enhances Mesothelioma Chemotherapy appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.
[…]
The U.S. Food and Drug Administration awarded Fast Track designation recently to the WT1 cancer vaccine, moving it closer to becoming the first approved second-line treatment for malignant pleural mesothelioma. The vaccine, also known as galinpepimut-S, is an immunotherapy agent that targets the WT1 protein, which is expressed in high levels in various cancers, such…
The post FDA Speeds Possible Second-Line Treatment for Mesothelioma appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.
[…]
The National Comprehensive Cancer Network (NCCN) has changed its first-line treatment recommendation for unresectable pleural mesothelioma, believing it will extend patient survival significantly. The NCCN advisory panel recently added the monoclonal antibody bevacizumab to the long-standing chemotherapy combination of pemetrexed and cisplatin. Bevacizumab, also known by brand name Avastin, inhibits the formation of new blood…
The post New Mesothelioma Treatment Guidelines May Extend Survival appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.
[…]
The National Comprehensive Cancer Network (NCCN) has changed its first-line treatment recommendation for unresectable pleural mesothelioma, believing it will extend patient survival significantly. The NCCN advisory panel recently added the monoclonal antibody bevacizumab to the long-standing chemotherapy combination of pemetrexed and cisplatin. Bevacizumab, also known by brand name Avastin, inhibits the formation of new blood…
The post New Mesothelioma Treatment Guidelines May Extend Survival appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.
[…]
The National Comprehensive Cancer Network (NCCN) has changed its first-line treatment recommendation for unresectable pleural mesothelioma, believing it will extend patient survival significantly. The NCCN advisory panel recently added the monoclonal antibody bevacizumab to the long-standing chemotherapy combination of pemetrexed and cisplatin. Bevacizumab, also known by brand name Avastin, inhibits the formation of new blood…
The post New Mesothelioma Treatment Guidelines May Extend Survival appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.
[…]
|
